EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›UPXI

UPXI

UPEXI, INC.

Next earnings Sep 18, 2026 · consensus $-0.12 EPS, $7.72M rev

Last earnings +3.0% on 2026-05-13

Avoid
$0.88
▲ +6.02%
$0.88▼ -72.15%
over 1Y
L $0.57EODHDH $8.56
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.0%
1W+15.8%
1M-17.8%
3M-9.7%
YTD-53.9%
1Y-72.2%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
D
Valuation
Fair value
Filings
Flagged
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy

A shrinking consumer-brands shell repurposed into a levered, dilution-funded Solana bet — a speculation, not an investable business.

Revenue $15.8M · FY2025

Upexi is no longer really a consumer-products company; per the MD&A it is 'in the cryptocurrency industry and the management of cash assets through a cryptocurrency portfolio, primarily focused in Solana.' The legacy branded-products business is in outright decline: FY2025 revenue fell 39% to $15.8M (management cites a 43% drop, driven ~85% by divesting the recommerce business), and the five-year trajectory is ugly — $24.1M (2021) → $23.1M → $36.4M → $26.0M → $15.8M, with net losses every year since 2021 totaling well over $50M (accumulated deficit -$60.5M). Operating margin is -79% and operating cash flow was -$8.4M. Only ~$985K of revenue came from the new digital-asset treasury. This is a business shrinking into a crypto holding vehicle.

The balance sheet looks superficially strong — total assets jumped 427% to $124M and equity 1,283% to $90.1M — but that expansion came entirely from issuing stock: shares outstanding exploded 5,557% (to 58.9M) to fund Solana purchases. So the $90M of equity is largely a pile of SOL tokens, an asset whose value is volatile and unknowable from this filing. Meanwhile actual cash is just $2.98M against $20.0M of current debt, and the Risk Factors explicitly warn of further dilution ('You may experience additional dilution in the future') and a 'limited operating history' with no assurance of ever reaching profitability.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$24.1M$23.1M$36.4M$26.0M$15.8M
Gross profit$11.9M$14.9M$21.0M$12.8M$10.9M
Operating income$1.43M-$6.49M-$12.3M-$22.5M-$12.5M
Net income$2.98M-$2.05M-$17.5M-$23.7M-$13.7M
Diluted EPS$0.21-$0.43-$18.94-$23.03-$1.73
Net margin12.4%-8.9%-48.0%-91.0%-86.5%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$111M
EV / EBITDA—
EV / Sales7.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-20.6%
FCF yield-13.3%

Quality & risk

ROIC (est.)-7.2%
Free cash flow-$8.81M
Total debt$47.7M
Net cash-$44.8M
Piotroski F-Score4/8

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+5557.4%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has skewed negative — read the flagged items.
  1. 8-K Other event2026-06-30

    Other-events press release, likely a Solana-treasury update; no P&L or structural change

  2. 8-K Delisting notice2026-06-26

    Received Nasdaq deficiency notice—sub-$1 bid price now threatens continued listing

  3. 8-K Material agreement2026-06-25

    New financing agreement + unregistered share sale to fund SOL treasury; dilutive

  4. 8-K Material agreement2026-06-24

    Announced material deal + unregistered equity raise (Reg FD); further dilution

  5. 8-K Shareholder vote2026-06-16

    Reported annual-meeting voting results; routine governance, no financial impact

  6. 8-K Earnings results2026-05-13

    Released Q3 FY26 results; core sales still shrinking, operating losses continue

  7. 10-Q Quarterly report2026-05-12

    Q3 FY26: ongoing operating losses; Solana treasury now core balance-sheet asset

  8. DEF 14A Proxy statement2026-05-05

    Filed proxy for annual meeting—director elections/routine votes; no financial change

  9. 10-Q Quarterly report2026-02-10

    Q2 FY26: continued losses; SOL treasury strategy scaling on the balance sheet

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-302026-06-30open ↗DFiling2026-06-29open ↗8-KPeriod ending 2026-06-242026-06-26open ↗8-KPeriod ending 2026-06-222026-06-25open ↗8-KPeriod ending 2026-06-212026-06-24open ↗8-KPeriod ending 2026-06-152026-06-16open ↗SCHEDULE 13G/AFiling2026-05-15open ↗8-KPeriod ending 2026-05-122026-05-13open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-052026-05-07open ↗DEF 14APeriod ending 2026-06-152026-05-05open ↗SCHEDULE 13GFiling2026-04-30open ↗

Quality score

D
ValueGrowthProfitHealthMom.
ValueC
GrowthC
ProfitabilityF
Financial healthC
MomentumF
  • ✗Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
0.5652-week8.55
Revenue
$15.8M
-39.2% YoY
Net margin
-86.5%
ROE
-15.2%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$15.8M-39.2%
Net income-$13.7M+42.2%
Gross profit$10.9M-15.3%
Operating income-$12.5M+44.4%
Diluted EPS-$1.73+92.5%
Cash & equivalents$2.98M+349.8%
Total assets$124M+426.6%
Stockholders' equity$90.1M+1282.7%
Gross: 68.7%Op.: -79.1%

Frequently asked

Is UPEXI, INC. (UPXI) a buy?
UPXI currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. A shrinking consumer-brands shell repurposed into a levered, dilution-funded Solana bet — a speculation, not an investable business.
What is UPEXI, INC.'s quality score?
UPXI scores 42.700902734844256/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001775194, latest 10-Q filed 2026-05-12) · EODHD · Proprietary analysis · as of 7/3/2026, 4:42:24 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2025-12-23-05:00
MARSHALL ALLAN
Chief Executive Officer
Buy50.0K @ $1.80$90.0K
2025-12-16-05:00
MARSHALL ALLAN
Chief Executive Officer
Buy50.0K @ $2.07$103K
2025-12-15-05:00
MARSHALL ALLAN
Chief Executive Officer
Buy100K @ $2.07$207K
2025-11-20-05:00
Salkind Gene
Director
Buy50.0K @ $2.55$127K
2025-11-17-05:00
Salkind Gene
Director
Buy100K @ $2.65$265K
2025-11-17-05:00
Salkind Gene
Director
Buy100K @ $2.81$281K
2025-10-01-05:00
MARSHALL ALLAN
Chief Executive Officer
Award1.60M
2025-10-01-05:00
Norstrud Andrew James
Chief Financial Officer
Award240K
2025-07-22-05:00
Dugan Lawrence
Director
Buy4.00K @ $7.50$30.0K
2025-07-16-05:00
Salkind Gene
Director
Award50.0K
2025-07-16-05:00
Salkind Gene
Director
Award150K
2025-07-16-05:00
Rudick Brian Benjamin
CSO
Award400K

Earnings history

beat/miss · move
2026-05-13Miss -718.6% est▲ +2.96%8-K ↗
2026-02-10Miss -5664.7% est▼ -7.14%8-K ↗
2025-11-12—▲ +5.30%8-K ↗
2025-09-26Miss -5664.7% est▼ -1.23%8-K ↗
2025-05-16—▲ +6.37%8-K ↗
2024-12-23—▼ -10.63%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Most shorted consumer staple small caps dominated by Ridgetech, Beyond MeatBullish
seekingalpha.com· 2026-07-01
Pre-Market Movers: BYAH, LXEO, ELTX Swing BigBearish
nasdaq.com· 2026-06-15
Upexi, Inc. Q3 2026 Earnings Call SummaryBullish
finance.yahoo.com· 2026-05-15
Upexi GAAP EPS of -$1.67, revenue of $4.6M misses by $1.5MBearish
seekingalpha.com· 2026-05-12
Upexi targets yield growth and capital market innovation amid Solana-driven volatilityBullish
seekingalpha.com· 2026-02-11
Upexi Reports Fiscal Second Quarter 2026 Financial ResultsBullish
globenewswire.com· 2026-02-10

Vs tracked universe

compare →

1196 tracked peers · median

EDGAR Score43 vs 67
Revenue growth-39.2% vs 7.5%
Net margin-86.5% vs 10.0%
Return on equity-15.2% vs 12.0%
P/E— vs 26.2

News sentiment

EODHD · 4d
Bearish
-0.59
vs typical · 4 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.